Development and challenges in the treatment of advanced gallbladder cancer (Review)
- Authors:
- Bo Zhou
- Shi-Ran Zhang
- Geng Chen
-
Affiliations: Department of Hepatobiliary Surgery, Daping Hospital, Army Medical University, Chongqing 400042, P.R. China, Department of Hepatobiliary Surgery, Daping Hospital, Army Medical University, Chongqing 400042, P.R. China - Published online on: June 3, 2025 https://doi.org/10.3892/ol.2025.15128
- Article Number: 382
This article is mentioned in:
Abstract
|
Roa JC, García P, Kapoor VK, Maithel SK, Javle M and Koshiol J: Gallbladder cancer. Nat Rev Dis Primers. 8:692022. View Article : Google Scholar : PubMed/NCBI | |
|
Song X, Hu Y, Li Y, Shao R, Liu F and Liu Y: Overview of current targeted therapy in gallbladder cancer. Signal Transduct Target Ther. 5:2302020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Y, Yang M, Feng J, Wang X and Liu Y: Advances in immunotherapy for biliary tract cancers. Chin Med J (Engl). 137:524–532. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Schmidt MA, Marcano-Bonilla L and Roberts LR: Gallbladder cancer: Epidemiology and genetic risk associations. Chin Clin Oncol. 8(31)2019.PubMed/NCBI | |
|
Lau CSM, Zywot A, Mahendraraj K and Chamberlain RS: Gallbladder carcinoma in the United States: A population based clinical outcomes study involving 22,343 patients from the surveillance, epidemiology, and end result database (1973–2013). HPB Surg. 2017:15328352017. View Article : Google Scholar : PubMed/NCBI | |
|
Hickman L and Contreras C: Gallbladder cancer: Diagnosis, surgical management, and adjuvant therapies. Surg Clin North Am. 99:337–355. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Feo CF, Ginesu GC, Fancellu A, Perra T, Ninniri C, Deiana G, Scanu AM and Porcu A: Current management of incidental gallbladder cancer: A review. Int J Surg. 98:1062342022. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Ren M, Yu J, Hu M, Wang X, Ma W, Jiang X and Cui J: Single-cell RNA sequencing highlights the functional role of human endogenous retroviruses in gallbladder cancer. EBioMedicine. 85:1043192022. View Article : Google Scholar : PubMed/NCBI | |
|
Shen H, He M, Lin R, Zhan M, Xu S, Huang X, Xu C, Chen W, Yao Y, Mohan M and Wang J: PLEK2 promotes gallbladder cancer invasion and metastasis through EGFR/CCL2 pathway. J Exp Clin Cancer Res. 38:2472019. View Article : Google Scholar : PubMed/NCBI | |
|
Wacker F and Dewald C: Local and locoregional treatment of intrahepatic cholangiocarcinoma. Radiologe. 62:247–252. 2022.(In German). View Article : Google Scholar : PubMed/NCBI | |
|
Scott A, Wong P and Melstrom LG: Surgery and hepatic artery infusion therapy for intrahepatic cholangiocarcinoma. Surgery. 174:113–115. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Edeline J, Lamarca A, McNamara MG, Jacobs T, Hubner RA, Palmer D, Groot Koerkamp B, Johnson P, Guiu B and Valle JW: Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. Cancer Treat Rev. 99:1022582021. View Article : Google Scholar : PubMed/NCBI | |
|
Mondaca S, Yarmohammadi H and Kemeny NE: Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma. Surg Oncol Clin N Am. 28:717–729. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chang Y, Jeong SW, Young Jang J and Jae Kim Y: Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma. Int J Mol Sci. 21:81652020. View Article : Google Scholar : PubMed/NCBI | |
|
Ray CE Jr, Edwards A, Smith MT, Leong S, Kondo K, Gipson M, Rochon PJ, Gupta R, Messersmith W, Purcell T and Durham J: Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy inpatients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 24:1218–1226. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Larghi A, Rimbas M, Tringali A, Boškoski I, Rizzatti G and Costamagna G: Endoscopic radiofrequency biliary ablation treatment: A comprehensive review. Dig Endosc. 31:245–255. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Deufel CL, Furutani KM, Dahl RA, Grams MP, McLemore LB, Hallemeier CL, Neben-Wittich M, Martenson JA and Haddock MG: Technique for the administration of high-dose-rate brachytherapy to the bile duct using a nasobiliary catheter. Brachytherapy. 17:718–725. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Yin Z, Jin H, Ma T, Zhou Y, Yu M and Jian Z: A meta-analysis of long-term survival outcomes between Surgical resection and radiofrequency ablation in patients with a single hepatocellular carcinoma <2 cm (BCLC very early stage). Int J Surg. 56:61–67. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Gkika E, Hawkins MA, Grosu AL and Brunner TB: The evolving role of radiation therapy in the treatment of biliary tract cancer. Front Oncol. 10:6043872020. View Article : Google Scholar : PubMed/NCBI | |
|
Franzese C, Bonu ML, Comito T, Clerici E, Loi M, Navarria P, Franceschini D, Pressiani T, Rimassa L and Scorsetti M: Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: Single-institution analysis of outcome and toxicity. J Cancer Res Clin Oncol. 146:2289–2297. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Bisello S, Buwenge M, Palloni A, Autorino R, Cellini F, Macchia G, Deodato F, Cilla S, Brandi G, Tagliaferri L, et al: Radiotherapy or chemoradiation in unresectable biliary cancer: A retrospective study. Anticancer Res. 39:3095–3100. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Komiyama S, Takeda A, Tateishi Y, Tsurugai Y, Eriguchi T and Horita N: Comparison of stereotactic body radiotherapy and transcatheter arterial chemoembolization for hepatocellular carcinoma: Systematic review and meta-analysis. Radiother Oncol. 202:1106142025. View Article : Google Scholar : PubMed/NCBI | |
|
Gkika E, Hallauer L, Kirste S, Adebahr S, Bartl N, Neeff HP, Fritsch R, Brass V, Nestle U, Grosu AL and Brunner TB: Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. BMC Cancer. 17:7812017. View Article : Google Scholar : PubMed/NCBI | |
|
Salgado SM, Gaidhane M and Kahaleh M: Endoscopic palliation of malignant biliary strictures. World J Gastrointest Oncol. 8:240–247. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sasaki T, Takeda T, Okamoto T, Ozaka M and Sasahira N: Chemotherapy for biliary tract cancer in 2021. J Clin Med. 10:3108–3122. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Yang L, Wang H, Guo M, He M, Zhang W, Zhan M and Liu Y: ELF3 promotes gemcitabine resistance through PKMYT1/CDK1 signaling pathway in gallbladder cancer. Cell Oncol (Dordr). 46:1085–1095. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Choi IS, Kim KH, Lee JH, Suh KJ and Kim JW, Park JH, Kim YJ, Kim JS, Kim JH and Kim JW: A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. Eur J Cancer. 154:288–295. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma A, Kalyan Mohanti B, Pal Chaudhary S, Sreenivas V, Kumar Sahoo R, Kumar Shukla N, Thulkar S, Pal S, Deo SV, Pathy S, et al: Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial. Eur J Cancer. 123:162–170. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 362:1273–1281. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, Ozaka M, Okano N, Sugimori K, Fukutomi A, et al: Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: The FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 30:1950–1958. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V, Raina V, Shukla NK, Thulkar S, Garg P and Chaudhary SP: Best supportive care compared with chemotherapy for unresectable gallbladder cancer: A randomized controlled study. J Clin Oncol. 28:4581–4586. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lai J, Yang S, Lin Z, Huang W, Li X, Li R, Tan J and Wang W: Update on chemoresistance mechanisms to first-line chemotherapy for gallbladder cancer and potential reversal strategies. Am J Clin Oncol. 46:131–141. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, Thomas CR Jr, Alberts SR, Dawson LA, Micetich KC, et al: SWOG S0809: A phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 33:2617–2622. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K, et al: Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): A phase 3, open-label, randomized, controlled trial. Lancet Oncol. 22:690–701. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Dodagoudar C, Doval DC, Mahanta A, Goel V, Upadhyay A, Goyal P, Talwar V, Singh S, John MC, Tiwari S and Patnaik N: FOLFOX-4 as second-line therapy after failure of gemcitabine and platinum combination in advanced gall bladder cancer patients. Jpn J Clin Oncol. 46:57–62. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Edeline J, Touchefeu Y, Guiu B, Farge O, Tougeron D, Baumgaertner I, Ayav A, Campillo-Gimenez B, Beuzit L, Pracht M, et al: Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial. JAMA Oncol. 6:51–59. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Y, Yuan K, Yang Y, Ji Z, Zhou D, Ouyang J, Wang Z, Wang F, Liu C, Li Q, et al: Gallbladder cancer: Current and future treatment options. Front Pharmacol. 14:11836192023. View Article : Google Scholar : PubMed/NCBI | |
|
Schmid S, Jochum W, Padberg B, Demmer I, Mertz KD, Joerger M, Britschgi C, Matter MS, Rothschild SI and Omlin A: How to read a next-generation sequencing report-what oncologists need to know. ESMO Open. 7:1005702022. View Article : Google Scholar : PubMed/NCBI | |
|
McCombie WR, McPherson JD and Mardis ER: Next-generation sequencing technologies. Cold Spring Harb Perspect Med. 9:a0367982019. View Article : Google Scholar : PubMed/NCBI | |
|
Kuipers H, de Bitter Tjjde Boer MT, van der Post RS, Nijkamp MW, de Reuver PR, Fehrmann RSN and Hoogwater FJH: Gallbladder cancer: Current insights in genetic alterations and their possible therapeutic implications. Cancers (Basel). 13:52572021. View Article : Google Scholar : PubMed/NCBI | |
|
Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S, et al: Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer. 122:3838–3847. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Roa I, Garcia H, Game A, de Toro G, de Aretxabala X and Javle M: Somatic mutations of PI3K in early and advanced gallbladder cancer: Additional options for an orphan cancer. J Mol Diagn. 18:388–394. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Dixit R, Pandey M, Tripathi SK, Dwivedi AN and Shukla VK: Comparative analysis of mutational profile of sonic hedgehog gene in gallbladder cancer. Dig Dis Sci. 62:708–714. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yang P, Javle M, Pang F, Zhao W, Abdel-Wahab R, Chen X, Meric-Bernstam F, Chen H, Borad MJ, Liu Y, et al: Somatic genetic aberrations in gallbladder cancer: Comparison between Chinese and US patients. Hepatobiliary Surg Nutr. 8:604–614. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kim RD, Sanoff HK, Poklepovic AS, Soares H, Kim J, Lyu J, Liu Y, Nixon AB and Kim DW: A multi-institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. Cancer. 126:3464–3470. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lee CK, Chon HJ, Cheon J, Lee MA, Im HS, Jang JS, Kim MH, Park S, Kang B, Hong M, et al: Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14). Lancet Gastroenterol Hepatol. 8:56–65. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Costello BA, Borad MJ, Qi Y, Kim GP, Northfelt DW, Erlichman C and Alberts SR: Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors. Investig. New Drugs. 32:710–716. 2014. View Article : Google Scholar | |
|
Bekaii-Saab TS, Yaeger R, Spira AI, Pelster MS, Sabari JK, Hafez N, Barve M, Velastegui K, Yan X, Shetty A, et al: Adagrasib in advanced solid tumors harboring a KRASG12C mutation. J Clin Oncol. 41:4097–4106. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Kastenhuber ER and Lowe SW: Putting p53 in Context. Cell. 170:1062–1078. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Vousden KH and Lane DP: p53 in health and disease. Nat Rev Mol Cell Biol. 8:275–283. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Levine AJ: p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer. 20:471–480. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Kennedy MC and Lowe SW: Mutant p53: It's not all one and the same. Cell Death Differ. 29:983–987. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Ajiki T, Onoyama H, Yamamoto M, Asaka K, Fujimori T, Maeda S and Saitoh Y: p53 protein expression and prognosis in gallbladder carcinoma and premalignant lesions. Hepatogastroenterology. 43:521–526. 1996.PubMed/NCBI | |
|
Zhao C, Yang ZY, Zhang J, Li O, Liu SL, Cai C, Shu YJ, Pan LJ, Gong W and Dong P: Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway. J Transl Med. 20:4342022. View Article : Google Scholar : PubMed/NCBI | |
|
Nepal C, Zhu B, O'Rourke CJ, Bhatt DK, Lee D, Song L, Wang D, Van Dyke AL, Choo-Wosoba H, Liu Z, et al: Integrative molecular characterisation of gallbladder cancer reveals micro-environment-associated subtypes. J Hepatol. 74:1132–1144. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Stancu M, Caruntu ID, Sajin M, Giuşca S, Badescu A and Dobrescu G: Immunohistochemical markers in the study of gallbladder premalignant lesions and cancer. Rev Med Chir Soc Med Nat Iasi. 111:734–743. 2007.PubMed/NCBI | |
|
National Library of Medicine, . Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder. https://ClinicalTrials.gov/show/NCT05512377 | |
|
Pilley S, Rodriguez TA and Vousden KH: Mutant p53 in cell-cell interactions. Genes Dev. 35:433–448. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Agupitan AD, Neeson P, Williams S, Howitt J, Haupt S and Haupt Y: p53: A guardian of immunity becomes its saboteur through mutation. Int J Mol Sci. 21:34522020. View Article : Google Scholar : PubMed/NCBI | |
|
Efe G, Rustgi AK and Prives C: p53 at the crossroads of tumor immunity. Nat Cancer. 5:983–995. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Guo XF, Zhang YY, Kang J, Dou QH and Zhu XF: A bispecific decoy receptor VEGFR-EGFR/Fc binding EGF-like ligands and VEGF shows potent antitumor efficacy. J Drug Target. 30:302–312. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Hung MS, Chen IC, Lin PY, Lung JH, Li YC, Lin YC, Yang CT and Tsai YH: Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer. Oncol Lett. 12:4598–4604. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Singh P, Jain SL, Sakhuja P and Agarwal A: Expression of VEGF-A, HER2/neu, and KRAS in gall bladder carcinoma and their correlation with clinico-pathological parameters. Indian J Pathol Microbiol. 64:687–692. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Xu D, Li J, Jiang F, Cai K and Ren G: The effect and mechanism of vascular endothelial growth factor (VEGF) on tumor angiogenesis in gallbladder carcinoma. Iran J Public Health. 48:713–721. 2019.PubMed/NCBI | |
|
De Lorenzo S, Garajova I, Stefanini B and Tovoli F: Targeted therapies for gallbladder cancer: An overview of agents in preclinical and clinical development. Expert Opin Investig Drugs. 30:759–772. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Mabeta P and Steenkamp V: The VEGF/VEGFR axis revisited: Implications for cancer therapy. Int J Mol Sci. 23:155852022. View Article : Google Scholar : PubMed/NCBI | |
|
Patel SA, Nilsson MB, Le X, Cascone T, Jain RK and Heymach JV: Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy. Clin Cancer Res. 29:30–39. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Ahamed A, Samanta A, Alam SSM, Mir SA, Jamil Z, Ali S and Hoque M: Nonsynonymous mutations in VEGF receptor binding domain alter the efficacy of bevacizumab treatment. J Cell Biochem. 125:e305152024. View Article : Google Scholar : PubMed/NCBI | |
|
Papadimitriou M and Papadimitriou CA: Antiangiogenic tyrosine kinase inhibitors in metastatic colorectal cancer: Focusing on regorafenib. Anticancer Res. 41:567–582. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Yan H, Wu W, Hu Y, Li J, Xu J, Chen X, Xu Z, Yang X, Yang B, He Q and Luo P: Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis. Nat Commun. 14:27562023. View Article : Google Scholar : PubMed/NCBI | |
|
Sahin IH, Tan E and Kim R: Regorafenib, an investigational agent for the treatment of cholangiocarcinoma. Expert Opin Investig Drugs. 30:333–341. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Yarden Y and Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol. 2:127–137. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Li M, Liu F, Zhang F, Zhou W, Jiang X, Yang Y, Qu K, Wang Y, Ma Q, Wang T, et al: Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: A whole-exome sequencing analysis. Gut. 68:1024–1033. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Augustin JE, Soussan P and Bass AJ: Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma. Ann Oncol. 33:1134–1148. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Fernandez AI, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, Harigopal M, Jorns JM, Kuba MG, Ly A, et al: Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. JAMA Oncol. 8:1–4. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Kam AE, Masood A and Shroff RT: Current and emerging therapies for advanced biliary tract cancers. Lancet Gastroenterol Hepatol. 6:956–969. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Merters J and Lamarca A: Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma. J Hepatol. 78:652–657. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Nam AR, Kim JW, Cha Y, Ha H, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, et al: Therapeutic implication of HER2 in advanced biliary tract cancer. Oncotarget. 7:58007–58021. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
National Library of Medicine, . Trastuzumab-pkrb Combined With Modified FOLFOX-6 in Biliary Tract Cancer Patients Progressed on First Line Therapy. https://ClinicalTrials.gov/show/NCT04722133 | |
|
Peng Y, Wang Y, Zhou C, Mei W and Zeng C: PI3K/Akt/mTOR pathway and its role in cancer therapeutics: Are we making headway? Front Oncol. 12:8191282022. View Article : Google Scholar : PubMed/NCBI | |
|
Lavacchi D, Caliman E, Rossi G, Buttitta E, Botteri C, Fancelli S, Pellegrini E, Roviello G, Pillozzi S and Antonuzzo L: Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions. Pharmacol Ther. 237:1081702022. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Jiang W, Liu S, Shi K, Zhang Y, Chen Y, Shan J, Wang Y, Xu X, Li C and Li X: Exosome-derived miR-182-5p promoted cholangiocarcinoma progression and vasculogenesis by regulating ADK/SEMA5a/PI3K pathway. Liver Int. 44:370–388. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Narayanankutty A: PI3K/akt/mTOR pathway as a therapeutic target for colorectal cancer: A review of preclinical and clinical evidence Curr. Drug Targets. 20:1217–1226. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Rosenberg L, Yoon CH, Sharma G, Bertagnolli MM and Cho NL: Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways. Carcinogenesis. 39:681–688. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Cai C, Dang W, Liu S, Huang L, Li Y, Li G, Yan S, Jiang C, Song X, Hu Y and Gu J: Anthrax toxin receptor 1/tumor endothelial marker 8 promotes gastric cancer progression through activation of the PI3K/AKT/mTOR signaling pathway. Cancer Sci. 111:1132–1145. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu H, Liu C, Wang M, Sun D, Zhu P, Zhang P, Tan X and Shi G: Tanshinone IIA affects the malignant growth of Cholangiocarcinoma cells by inhibiting the PI3K-Akt-mTOR pathway. Sci Rep. 11:192682021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, Yang W, Tian C, Miao Z, Wang T and Yang S: Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives. Signal Transduct Target Ther. 6:2012021. View Article : Google Scholar : PubMed/NCBI | |
|
Barbacid M: ras genes. Annu Rev Biochem. 56:779–827. 1987. View Article : Google Scholar : PubMed/NCBI | |
|
Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, Laguer J, Medwid J, Vanderpool D, Lifset E, et al: Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med. 8:2171–2182. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu C, Guan X, Zhang X, Luan X, Song Z, Cheng X, Zhang W and Qin JJ: Targeting KRAS mutant cancers: From druggable therapy to drug resistance. Mol Cancer. 21:1592022. View Article : Google Scholar : PubMed/NCBI | |
|
Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S and Westover KD: Biochemical and structural analysis of common cancer-associated KRAS mutations. Mol Cancer Res. 13:1325–1335. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Huang L, Guo Z, Wang F and Fu L: KRAS mutation: From undruggable to druggable in cancer. Signal Transduct Target Ther. 6:3862021. View Article : Google Scholar : PubMed/NCBI | |
|
Nagao M, Fukuda A, Omatsu M, Namikawa M, Sono M, Fukunaga Y, Masuda T, Araki O, Yoshikawa T, Ogawa S, et al: Concurrent activation of Kras and canonical Wnt signaling induces premalignant lesions that progress to extrahepatic biliary cancer in mice. Cancer Res. 82:1803–1817. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, Mueller B, Quaratino S, Sabatos-Peyton C, Petruzzelli L, et al: Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 17:286–301. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al: Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 13:54–61. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu H, Shan Y, Ge K, Lu J, Kong W and Jia C: Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy. Cell Oncol (Dordr). 43:1203–1214. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yi M, Zheng X, Niu M, Zhu S, Ge H and Wu K: Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer. 21:282022. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L, Tang K, Li X and Lu W: Anti-PD-1-based immunotherapy plus lenvatinib to treat advanced gallbladder cancer in the elderly: A case series and review of current literature. J Cancer Res Clin Oncol. 149:941–950. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Patel SP, Guadarrama E, Chae YK, Dennis MJ, Powers BC, Liao CY, Ferri WA Jr, George TJ, Sharon E, Ryan CW, et al: SWOG 1609 cohort 48: Anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer. Cancer. 130:2918–2927. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Zheng Q, Wu C, Ye H, Xu Z, Ji Y, Rao J, Lu L, Zhu Y and Cheng F: Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cancer. Ann Transl Med. 9:15682021. View Article : Google Scholar : PubMed/NCBI | |
|
Jalili-Nik M, Soltani A, Mashkani B, Rafatpanah H and Hashemy SI: PD-1 and PD-L1 inhibitors foster the progression of adult T-cell Leukemia/Lymphoma. Int Immunopharmacol. 98:1078702021. View Article : Google Scholar : PubMed/NCBI | |
|
Zuo H and Wan Y: Inhibition of myeloid PD-L1 suppresses osteoclastogenesis and cancer bone metastasis. Cancer Gene Ther. 29:1342–1354. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, et al: Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): A randomized, double-blind, phase 3 trial. Lancet. 399:1718–1729. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y and Xia Y: Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 15:242022. View Article : Google Scholar : PubMed/NCBI | |
|
Chu X, Tian W, Wang Z, Zhang J and Zhou R: Co-inhibition of TIGIT and PD-1/PD-L1 in cancer immunotherapy: Mechanisms and clinical trials. Mol Cancer. 22:932023. View Article : Google Scholar : PubMed/NCBI | |
|
Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, Wu W, Han L and Wang S: The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 13:9644422022. View Article : Google Scholar : PubMed/NCBI | |
|
Xie Q, Wang L and Zheng S: Prognostic and clinicopathological significance of PD-L1 in patients with cholangiocarcinoma: A meta-analysis. Dis Markers. 2020:18179312020. View Article : Google Scholar : PubMed/NCBI | |
|
Xia L, Liu Y and Wang Y: PD-1/PD-L1 blockade therapy in advanced non-small cell lung cancer: Current status and future directions. Oncologist. 24 (Suppl 1):S31–S41. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Aguiar PN Jr, De Mello RA, Hall P, Tadokoro H and Lima Lopes G: PD-L1 expression as a predictive biomarker in advanced non-small cell lung cancer: Updated survival data. Immunotherapy. 9:499–506. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, Zeng WJ, Liu Z and Cheng Q: Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res. 40:1842021. View Article : Google Scholar : PubMed/NCBI | |
|
Sznol M and Melero I: Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy. Ann Oncol. 32:295–297. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Rotte A: Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 38:2552019. View Article : Google Scholar : PubMed/NCBI | |
|
Doki Y, Ueno M, Hsu CH, Oh DY, Park K, Yamamoto N, Ioka T, Hara H, Hayama M, Nii M, et al: Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer. Cancer Med. 11:2550–2560. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Zhu L, Zhang H, Chen S and Xiao Y: CAR-T cell therapy in hematological malignancies: Current opportunities and challenges. Front Immunol. 13:9271532022. View Article : Google Scholar : PubMed/NCBI | |
|
Goyco Vera D, Waghela H, Nuh M, Pan J and Lulla P: Approved CAR-T therapies have reproducible efficacy and safety in clinical practice. Hum Vaccin Immunother. 20:23785432024. View Article : Google Scholar : PubMed/NCBI | |
|
National Library of Medicine, . Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma. https://ClinicalTrials.gov/show/NCT03159819 | |
|
Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, Dahiya S, Beitinjaneh AM, Jacobs MT, Mcguirk JP, et al: Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: Results from the US lymphoma CAR T consortium. J Clin Oncol. 41:2594–2606. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Depil S, Duchateau P, Grupp SA, Mufti G and Poirot L: ‘Off-the-shelf’ allogeneic CAR T cells: Development and challenges. Nat Rev Drug Discov. 19:185–199. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Sterner RC and Sterner RM: CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J. 11:692021. View Article : Google Scholar : PubMed/NCBI | |
|
Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan CX and Zhu Z: CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 41:1192022. View Article : Google Scholar : PubMed/NCBI | |
|
Ma S, Li X, Wang X, Cheng L, Li Z, Zhang C, Ye Z and Qian Q: Current progress in CAR-T cell therapy for solid tumors. Int J Biol Sci. 15:2548–2560. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Faghfuri E, Pourfarzi F, Faghfouri AH, Abdoli Shadbad M, Hajiasgharzadeh K and Baradaran B: Recent developments of RNA-based vaccines in cancer immunotherapy. Expert Opin Biol Ther. 21:201–218. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Malacopol AT and Holst PJ: Cancer vaccines: Recent insights and future directions. Int J Mol Sci. 25:112562024. View Article : Google Scholar : PubMed/NCBI | |
|
Miao L, Zhang Y and Huang L: mRNA vaccine for cancer immunotherapy. Mol Cancer. 20:412021. View Article : Google Scholar : PubMed/NCBI | |
|
Binda C, Anderloni A, Fugazza A, Amato A, de Nucci G, Redaelli A, Di Mitri R, Cugia L, Pollino V, Macchiarelli R, et al: EUS-guided gallbladder drainage using a lumen-apposing metal stent as rescue treatment for malignant distal biliary obstruction: A large multicenter experience. Gastrointest Endosc. 98:765–773. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Benson AB, D'Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, Bachini M, Borad M, Brown D, Burgoyne A, et al: Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 19:541–565. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Strang P: Palliative oncology and palliative care. Mol Oncol. 16:3399–3409. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Beasley AM, Bakitas MA, Ivankova N and Shirey MR: Evolution and conceptual foundations of nonhospice palliative care. West J Nurs Res. 41:1347–1369. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kozlov E, Niknejad B and Reid MC: Palliative care gaps in providing psychological treatment: A review of the current state of research in multidisciplinary palliative care. Am J Hosp Palliat Care. 35:505–510. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Tondorf T, Grossert A, Rothschild SI, Koller MT, Rochlitz C, Kiss A, Schaefert R, Meinlschmidt G, Hunziker S and Zwahlen D: Focusing on cancer patients' intentions to use psychooncological support: A longitudinal, mixed-methods study. Psychooncology. 27:1656–1663. 2018. View Article : Google Scholar : PubMed/NCBI |
